
Verastem Oncology Highlights RAMP 201 Data for Avutometinib and Defactinib in Ovarian Cancer at IGCS 2024
Verastem Oncology Reports Promising RAMP 201 Data for Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer Verastem Oncology has announced encouraging results from its Phase 2 RAMP 201 trial, showcasing…












